scholarly article | Q13442814 |
P819 | ADS bibcode | 2019NatCo..10..610R |
P6179 | Dimensions Publication ID | 1111912077 |
P356 | DOI | 10.1038/S41467-019-08528-Z |
P932 | PMC publication ID | 6363798 |
P698 | PubMed publication ID | 30723225 |
P50 | author | Freya Fowkes | Q42800053 |
Michelle J Boyle | Q55174963 | ||
Danny W Wilson | Q56476038 | ||
Ivo Mueller | Q60043791 | ||
Takafumi Tsuboi | Q63860522 | ||
Linda Reiling | Q118533572 | ||
P2093 | author name string | Michael T White | |
James G Beeson | |||
Eizo Takashima | |||
Peter M Siba | |||
Jack S Richards | |||
Gaoqian Feng | |||
D Herbert Opi | |||
Kristina E M Persson | |||
Rupert Weaver | |||
P2860 | cites work | Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara | Q37220681 |
The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria | Q37239883 | ||
Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination | Q37459461 | ||
The future for blood-stage vaccines against malaria | Q37471465 | ||
The wheat germ cell-free protein synthesis system: a key tool for novel malaria vaccine candidate discovery | Q37632828 | ||
Malaria vaccines and human immune responses | Q38854831 | ||
Functional Antibodies and Protection against Blood-stage Malaria | Q38933541 | ||
High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya | Q39362550 | ||
Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. | Q39417737 | ||
Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection | Q44147641 | ||
Antibodies among men and children to placental-binding Plasmodium falciparum-infected erythrocytes that express var2csa. | Q46337040 | ||
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions | Q47576664 | ||
IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. | Q47830190 | ||
Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia | Q47954510 | ||
Evidence that the erythrocyte invasion ligand PfRh2 is a target of protective immunity against Plasmodium falciparum malaria | Q47957417 | ||
Gamma-globulin and acquired immunity to human malaria | Q47957467 | ||
Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese vi | Q48000659 | ||
Immunization of malaria pre-exposed volunteers with PfSPZ Vaccine elicits long-lived IgM invasion-inhibitory and complement-fixing antibodies | Q50041449 | ||
Identifying Immune Correlates of Protection Against Plasmodium falciparum Through a Novel Approach to Account for Heterogeneity in Malaria Exposure | Q50062994 | ||
Acquired immunity to malaria | Q24651173 | ||
Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria | Q26772878 | ||
Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases | Q26825548 | ||
Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase | Q27860571 | ||
Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians | Q33302903 | ||
Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. | Q33305467 | ||
Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum | Q33380204 | ||
Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults | Q33380213 | ||
The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis | Q33526349 | ||
Evaluation of the antigenic diversity of placenta-binding Plasmodium falciparum variants and the antibody repertoire among pregnant women | Q33826049 | ||
A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray | Q33859633 | ||
Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1 | Q33870167 | ||
Development of fluorescent Plasmodium falciparum for in vitro growth inhibition assays | Q33939788 | ||
Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine | Q34011922 | ||
Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial | Q34043843 | ||
Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development | Q34069682 | ||
Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans | Q34081745 | ||
High affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malaria | Q34171724 | ||
Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines | Q34416904 | ||
The Plasmodium falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human antibodies against malaria. | Q34428497 | ||
Research priorities for the development and implementation of serological tools for malaria surveillance | Q34500035 | ||
Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies | Q34680704 | ||
Antibodies to polymorphic invasion-inhibitory and non-Inhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malaria | Q34827195 | ||
Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria | Q35213495 | ||
New antigens for a multicomponent blood-stage malaria vaccine | Q35216634 | ||
A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens | Q36141540 | ||
Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies | Q36227228 | ||
Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine | Q36304234 | ||
Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. | Q36368911 | ||
Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? | Q36391845 | ||
Vaccine candidate discovery for the next generation of malaria vaccines. | Q36413834 | ||
Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development | Q36984161 | ||
The risk of malarial infections and disease in Papua New Guinean children. | Q37088901 | ||
Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness | Q37099503 | ||
Human antibodies activate complement against Plasmodium falciparum sporozoites, and are associated with protection against malaria in children. | Q52715900 | ||
Human immunization with a polymorphic malaria vaccine candidate induced antibodies to conserved epitopes that promote functional antibodies to multiple parasite strains. | Q53698025 | ||
The complement system contributes to functional antibody-mediated responses induced by immunization with Plasmodium falciparum malaria sporozoites. | Q55353878 | ||
Mouse strains with typical mammalian levels of complement activity | Q69418249 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | malaria | Q12156 |
P304 | page(s) | 610 | |
P577 | publication date | 2019-02-05 | |
P1433 | published in | Nature Communications | Q573880 |
P1476 | title | Targets of complement-fixing antibodies in protective immunity against malaria in children | |
P478 | volume | 10 |
Q92965786 | Antibodies against Plasmodium falciparum malaria at the molecular level |
Q99709750 | Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across seasons and transmission settings in The Gambia |
Q90107838 | Antibody-mediated complement activation in pathology and protection |
Q90300290 | Complement in malaria immunity and vaccines |
Q91918114 | Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives |
Q91712984 | Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA): a study protocol to investigate in vivo Plasmodium falciparum malaria parasite growth in the context of pre-existing immunity |
Q90450452 | IgM in human immunity to Plasmodium falciparum malaria |
Q89559305 | Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial |
Q92664225 | Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort |
Q104077094 | Seasonal malaria chemoprevention: closing the know-do gap |
Q110697512 | Serology for Plasmodium vivax surveillance: A novel approach to accelerate towards elimination |
Q104617066 | Th2-like T Follicular Helper Cells Promote Functional Antibody Production during Plasmodium falciparum Infection |
Q89516787 | The Blood Stage Antigen RBP2-P1 of Plasmodium vivax Binds Reticulocytes and Is a Target of Naturally Acquired Immunity |
Search more.